Related Experiment Video
Updated: Jun 8, 2026

Separating Bacteria by Capsule Amount Using a Discontinuous Density Gradient
Published on: January 7, 2019
Management of infections due to KPC-producing Klebsiella pneumoniae
Abstract:
The emergence of the Klebsiella pneumoniae carbapenemases in K. pneumoniae and other Gram-negative bacteria, usually on a background of multidrug resistance, has led to difficult therapeutic choices. Among available antibiotics, tigecycline and the polymyxins are the most frequently active against these organisms in vitro. Optimal therapy of infections due to these bacteria may involve maximization of antibiotic dose as well as their use in combination.
Insights
Klebsiella pneumoniae carbapenemases (KPC) present treatment challenges in multidrug-resistant Gram-negative bacteria. Tigecycline and polymyxins show in vitro activity, suggesting combination therapy and dose optimization may be key.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- The rise of Klebsiella pneumoniae carbapenemases (KPC) in Gram-negative bacteria, including K. pneumoniae, poses significant therapeutic challenges.
- These KPC-producing organisms often exhibit multidrug resistance, limiting treatment options.
Purpose of the Study:
- To review the therapeutic options for infections caused by KPC-producing Gram-negative bacteria.
- To highlight the role of tigecycline and polymyxins in treating these infections.
Main Methods:
- Literature review of antimicrobial activity against KPC-producing Gram-negative bacteria.
- Analysis of treatment strategies for infections caused by these pathogens.
Main Results:
- Tigecycline and polymyxins demonstrate the most consistent in vitro activity against KPC-producing Gram-negative bacteria.
- These agents are frequently the last-resort options for such infections.
Conclusions:
- Optimal management of KPC-producing Gram-negative bacterial infections may require maximizing antibiotic doses.
- Combination therapy with agents like tigecycline and polymyxins could be beneficial.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Atypical Pneumonia
Clinical Significance of Antibiotic Resistance
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
